Average customer rating:
|
The Cell Game: Sam Waksal's Fast Money and False Promises--and the Fate of ImClone's Cancer Drug
Alex Prud'homme Manufacturer: Collins ProductGroup: Book Binding: Hardcover Similar Items:
ASIN: 0060555564 Release Date: 2004-01-20 |
Book Description
It began with a promising cancer drug, the brainchild of a gifted researcher, and grew into an insider trading scandal that ensnared one of America's most successful women. The story of ImClone Systems and its "miracle" cancer drug, Erbitux, is the quintessential business saga of the late 1990s. It's the story of big money and cutting-edgescience, celebrity, greed, and slipshod business practices; the story of biotech hype and hope and every kind of excess.
At the center of it all stands a single, enigmatic figure named Sam Waksal. A brilliant, mercurial, and desperate-to-be-liked entrepreneur, Waksal was addicted to the trappings of wealth and fame that accrued to a darling of the stock market and the overheated atmosphere of biotech IPOs. At the height of his stardom, Waksal hobnobbed with Martha Stewart in New York and Carl Icahn in the Hamptons, hosted parties at his fabulous art-filled loft, and was a fixture in the gossip columns. He promised that Erbitux would "change oncology," and would soon be making $1 billion a year.
But as Waksal partied late into the night, desperate cancer patients languished, waiting for his drug to come to market. When the FDA withheld approval of Erbitux, the charming scientist who had always stayed just one step ahead of bankruptcy panicked and desperately tried to cash in his stock before the bad news hit Wall Street.
Waksal is now in jail, the first of the Enron-era white-collar criminals to be sentenced. Yet his cancer drug has proved more durable than his evanescent profits. Erbitux remains promising, the leading example of a new way to fight cancer, and patients and investors hope it will be available soon.
Customer Reviews:
Compelling tale about greed and how the system works.......2004-04-19
It is specifically about the rise and fall of one Sam Waksal, oldest son of Jewish emigrants and Holocaust survivors, a man of irresistible charm, fabulous energy, and great intelligence, a man driven to success and the high life, a man who had bounced around academia without much success until in the 1980s he saw an opportunity to become a player in the cancer game, and, along with his younger brother Harlan, founded ImClone Systems, Inc.
It is also about an anticancer drug called Erbitux, originally known as C225 because it was the 225th drug tested by its discoverers, John Mendelsohn and Gordon Sato in 1980. It showed promise because in tests it stopped the growth of tumors in mice.
And finally it is a story about how drugs get discovered, how they are developed, and especially how they get approved (or not) by the Food and Drug Administration. And of course it is about the Byzantine and incestuous relationship that exists between that August government agency and the massive pharmaceutical industry.
The curious thing about all this is that Imclone never turned a profit, Erbitux never came to market, and most of the people associated with Waksal and ImClone either made out like bandits or got stuck holding the bag. The drug itself, which works against cancer tumors, particularly colon cancer, by cutting off the blood supply to the tumors (an "antiangiogenesis" drug), was touted as a miracle that would save the lives of innumerable patients and make possibly billions of dollars for ImClone.
At least this was the hype delivered by Sam Waksal, and bought hook, line and sinker by pharma giant Bristol-Myers Squibb, and by desperate cancer patients as well as salivating Wall Street investors who jumped on the bandwagon as ImClone's stock rocketed skyward. Because of the promise of the drug, Waksal himself was able to live his dream life as a New York socialite, throwing lavish parties for celebs (including Martha Stewart while he dated her daughter), collecting fine art, popping open $600 bottles of Chateau Lafite-Rothschild while secretly selling stock on the side, sending the proceeds overseas, buying expensive apartments and houses for himself, etc., etc.
But the cold hard facts of Erbitux, like those of almost any cancer drug one can name, are very far from the hype. As Prud'homme notes on pages 332-333, "these agents...[Erbitux and others like Avastin and Iressa] are remarkable scientific advances, [but] they still only benefit some 10 to 20 percent of patients, and they only extend patients' lives by a matter of months."
That's it. That's the bottom line. And yet these drugs are so valuable that the companies that end up selling them can make hundreds of millions if not billions of dollars.
Waksal apparently came to this understanding sometime during the early eighties. He realized first the simple fact that the way the cancer industry works is doctors have to prescribe something rather than nothing. Then he realized that living a few months longer can mean a lot to people. Therefore any FDA-approved cancer drug will automatically fill a need. What this means is that the PROMISE of a cancer drug, if cleverly promoted, will spark a rally in the shares of the company that owns the patent. If, like Sam Waksal, you own millions of those shares, you can get rich on mere promise alone.
Furthermore, should the drug have any real value at all, and be approved (or even look like it's going to be approved) by the FDA, you might be able to get some pharmaceutical giant like Bristol-Myers Squibb to front a whole lot of money on that promise since they are desperate to find a cancer drug to replace those that have gone generic.
This works because even drugs with very limited effectiveness are better than no drug at all. This is true for many patients, for many doctors, and is especially true for the big pharmaceutical companies.
Note that these drugs are valuable because the people who need them are typically people of relative means who can afford to pay large sums of money for them, either through their HMOs, their government, or their own funds. In contrast a drug that would prolong the life of poor people in third world countries would be of only marginal value to the big pharmaceutical companies.
I should also mention that Prud'homme spends some serious ink in this book on Waksal's long-time friend Martha Stewart and her troubles. Her personality, her empire, and the way she handles herself are vividly detailed. In fact, some readers might find her story the most interesting part of the book.
Reads like a novel, but it's a true story.......2004-02-22
Sam Waksal, a scientist and business developer with a checkered past, lives a celebrity lifestyle, hanging out with the rich and famous, owning several fancy houses, driving fast cars, and heading a firm that is working on a cancer drug so promising that people with no other hope of treatment are flinging themselves at ImClone, begging for a merciful dose of "Erbitux."
The drug apparently does reverse inoperable tumors in a few test patients who had no other hope of living. Now the race is on to fast-track the drug through the FDA approval process based on the glowing clinical trials. But the FDA reviewer is unaccountably unencouraging when meeting with one of ImClone's top scientists. What is wrong? Is Erbitux, instead of being approved , instead going have its application refused? Why! And what will this mean for the high-flying ImClone stock?
The book reads like the best thriller, and author Alex Prud'homme is adept at making you feel like the proverbial fly-on-the-wall during the action. If you are at all interested in what happened behind the Martha Stewart debacle, you must read this. It's fantastic.
Lively character study about Sam Waksal - needless tragedy.......2004-02-15
It is amazingly sad that all of this misery was so pointless because Erbitux has at last been approved. It almost certainly could have been approved earlier if the talented team at ImClone would have had a culture of discipline and getting things done and documented in ways that everyone knew the FDA required. If they had, all this pain and loss would never have occurred and Dr. Waksal would be a real hero instead of the one he only pretended to be.
Mr. Prud'homme writes with style and vitality. The book moves along well and has a great feel for keeping the story personal and emotionally accessible for the reader. We don't get overwhelmed with the scientific side of things, although it is always interesting to read about this emerging science and the wizards who are making it happen.
A GRIPPING YARN!!!!.......2004-01-28
The Waksal-Stewart Connection.......2004-01-27
Average customer rating:
|
Creating Paths of Change: Managing Issues and Resolving Problems in Organizations
Will McWhinney , James B. Webber , Douglas M. Smith , and Bernie J. Novokowsky Manufacturer: Sage Publications, Inc ProductGroup: Book Binding: Paperback Similar Items:
ASIN: 0761910077 Release Date: 1997-05-07 |
Book Description
Individuals, organizations, and communities constantly engage in change. Creating Paths of Change is a provides the reader with a proven strategy for making changes and resolving issues more effectively. This effective workbook is written for individuals and groupsùmanagers, entrepreneurs, and consultants ûwho are taking responsibility for the change effort. It addresses the problems faced in the daily operations of organizational life, and provides a foundation and theory for effective and sustained issue resolution. Creating Paths of Change guides the reader, in a step-by-step fashion, through the change-making or decision-making process helping the reader identify and improve his or her personal problem-solving style. The book has been used by individual managers, community volunteers, organizational consultants in a number of settings, and has been thoroughly class-tested in university courses.Customer Reviews:
At last: the manual we were waiting for.......2002-05-23
Everything you always wanted to ask about change, but ..........2000-03-29
Average customer rating: |
Rural Politics: Policies for Agriculture, Forestry and the Environment
Michael Winter Manufacturer: Routledge ProductGroup: Book Binding: Hardcover ASIN: 0415081750 |
Book Description
The rural areas of Britain, Europe and the developed world are undergoing massive changes, with increasing concern about productivity, agricultural methods and environmental policy. Rural Politics examines the issues affecting rural areas, such as water pollution, forestry, and the greening of agricultural policy. It looks in particular at the political parameters surrounding these issues and how concern for the countryside is essentially part of a wider set of political processes.
Average customer rating: |
A Primer on Regression Artifacts
Donald T. Campbell , and David A. Kenny Manufacturer: The Guilford Press ProductGroup: Book Binding: Paperback Similar Items:
ASIN: 1572308591 |
Book Description
Average customer rating: |
Vectors: Essential Data
Peter Gacesa , and Dipak P. Ramji Manufacturer: John Wiley & Sons ProductGroup: Book Binding: Paperback ASIN: 0471948411 |
Book Description
The correct choice of vector is crucial to success in molecular biology. This volume brings together up-to-date information on the most widely used vectors for bacterial, mammalian, plant and yeast research and so will prove invaluable for all researches in these fields. The Essential Data series provides rapid access to the core data required by researchers on a daily basis, in convenient pocket-sized volumes.
Average customer rating:
|
Football's Best Offensive Playbook
Manufacturer: Human Kinetics Publishers ProductGroup: Book Binding: Paperback Similar Items:
ASIN: 0873225740 |
Book Description
Every offensive playbook gives you Xs and Os that look good on paper. Football's Best Offensive Playbook goes the extra yard, providing precisely illustrated plays that are proven point-producers in games.Each of the 100 running, passing, and special plays comes with a clear, accurate diagram and coaching pointers that highlight key player positions and responsibilities. Many coaches list alternate formations, and most of the plays can be adapted to any offensive system. A convenient Play Finder index lists plays by type of run, pass, and formation. And since the book features contributions from coaches at the high school, college, and pro ranks, you'll find plays that work at all levels.
Strengthen your playlist with help from many of the game's most successful coacheswith Football's Best Offensive Playbook.
Customer Reviews:
Good intro book.......2004-03-20
Outstanding Guide to Great Plays.......2003-03-10
Plays are broken down by type (off-tackle, options, quick passes, etc.), and by formation (predominantly I formation, but with a healthy mix of single back/spread, Wing-T, veer and even wishbone). Hawkes also makes it easy to locate plays by each coach who submitted them.
And what a group of coaches -- the greatest offensive minds in college and high school football for the last 20 years are represented here. Cross-referencing plays among coaches reveals insights into the differences a seemingly minor blocking variation can make in the success or failure of a play.
Highly recommended.
This is NOT a playbook!.......2001-04-16
The individual plays are well diagrammed and explained, as well as the philosophy behind their use, but there is no consistency within the book. You could not, for example, take this document to your football practice and install the plays with your high school team and expect to have a successful offense.
Rather, if you are running an offense SIMILAR to the offense of one of the coaches who contributed to the book, then you may find ONE OR TWO plays that you can add to your existing system. This is a far cry from being a "playbook" as the title claims.
I do not recommend this book for any coach below the high school level, or for parents wishing to learn the sport better. You will only be confused.
Hey coach, you need this book!.......2001-02-17
Awesome offensive playbook!.......2000-08-27
Average customer rating:
|
The Penguin Dictionary of Symbols (Dictionary, Penguin)
Jean Chevalier , and Alain Gheerbrant Manufacturer: Penguin (Non-Classics) ProductGroup: Book Binding: Paperback Similar Items:
ASIN: 0140512543 |
Customer Reviews:
Comprehensive..........2007-06-09
Disappointed with Amazon.......2006-06-20
An essential reference work.......2006-02-03
A book full of surprise.......2004-12-30
The Cadillac of Symbol Books.......2004-12-04
Average customer rating: |
Penguin Dictionary of Symbols
Jean Chevalier Manufacturer: Penguin ProductGroup: Book Binding: Paperback ASIN: B000K7ME7A |
Average customer rating: |
The Penguin Dictionary of Symbols - B Fmt
Chevalier Jean Et Al Manufacturer: Penguin (Non-Classics) ProductGroup: Book Binding: Paperback ASIN: B000OJ4G5W |
Average customer rating: |
In the Heart of the Temple: My Spiritual Vision for Today's World
Joan Chittister Manufacturer: Bluebridge ProductGroup: Book Binding: Paperback Similar Items:
ASIN: 0974240516 |
Book Description
Average customer rating: |
Oysters, pearls and irritation: Joan Chittister's anger is neither dimmed nor quenched.(Book Review): An article from: Presbyterian Record
Lee McKenna Du Charme Manufacturer: Thomson Gale ProductGroup: Book Binding: Digital ASIN: B000F3UD90 Release Date: 2006-03-21 |
Book Description
This digital document is an article from Presbyterian Record, published by Thomson Gale on March 1, 2006. The length of the article is 752 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Books:
Recommended Books